http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 03:34:25 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Seaport+Therapeutics+%28SPTX%29/26619233.html <p>Stifel analyst Paul Matteis reiterated a Buy rating and $30.00 price target on Seaport Therapeutics (NASDAQ: SPTX)</p><p>The analyst comments: “We're reiterating Buy on SPTX--timelines for their GlyphAllo/SPT-300 and GlyphAgo/ SPT-320 remain on-track. Highlighted in our recent initiation report (LINK), SPTX is leveraging their novel "Glyph" platform to significantly improve PK/bioavailability and/ or safety for two therapies--allopregnanalone and agomelatine--where the mechanism is at least somewhat validated, but there are drug limitations to improve upon. GlyphAllo is the lead program, and the MDD ph2b is enrolling with topline-data expected 1H27--SPTX plans to enroll the full 360 patient target sample size (no longer http://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Seaport+Therapeutics+%28SPTX%29/26619233.html Tue, 09 Jun 2026 03:34:25 -0400 SPTX http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html <p>Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.</p> <p>The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.</p> <p>The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html Tue, 09 Jun 2026 02:00:42 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html <p>Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.</p> <p>The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.</p> <p>The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html Tue, 09 Jun 2026 02:00:42 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html <p>Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.</p> <p>The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.</p> <p>The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html Tue, 09 Jun 2026 02:00:42 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html <p>Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.</p> <p>The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.</p> <p>The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html Tue, 09 Jun 2026 02:00:42 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html <p>Seaport Therapeutics Inc. (NASDAQ: SPTX) reported positive results from the multiple-ascending dose portion of its Phase 1 trial for GlyphAgo, an oral prodrug of agomelatine being developed for generalized anxiety disorder.</p> <p>The seven-day dosing study in healthy volunteers showed GlyphAgo achieved therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. The drug demonstrated consistent safety, tolerability and pharmacokinetic profiles across all trial portions, with no serious adverse events or liver-related safety issues observed.</p> <p>The Phase 1 trial included 174 participants across single-ascending dose, multiple-ascending dose and crossover portions. Previously reported crossover http://www.streetinsider.com/FDA/Seaport+Therapeutics+reports+positive+phase+1+data+for+GlyphAgo+anxiety+drug/26619129.html Tue, 09 Jun 2026 02:00:42 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Press+Releases/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html <p> BOSTON--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=73ff8387bfb1f47cda28dc3f5a1115f3" shape="rect">PureTech Health plc</a> (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretech-founded-entity-seaport-therapeutics-announces-positive&amp;esheet=54550124&amp;newsitemid=20260608428399&amp;lan=en-US&amp;anchor=previously+reported&amp;index=2&amp;md5=499bb68c4788112d6f9d3191736fcca4" shape="rect">previously reported</a> single-ascending dose (SAD) and crossover data, supporting its http://www.streetinsider.com/Business+Wire/PureTech+Founded+Entity+Seaport+Therapeutics+Reports+Positive+Multiple-Ascending+Dose+Data+from+Phase+1+Proof-of-Concept+Trial+of+GlyphAgo%E2%84%A2+in+Healthy+Volunteers/26619119.html Tue, 09 Jun 2026 02:00:00 -0400 A.26940647 O.22973220 O.56907606 PRTC SPTX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Seaport+Therapeutics%2C+++++For%3A+Mar+31/26614236.html si-local-file:///var/storage/secattach/20260608/26614236.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Seaport+Therapeutics%2C+++++For%3A+Mar+31/26614236.html Mon, 08 Jun 2026 07:16:00 -0400 SPTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seaport+Therapeutics%2C+++++For%3A+Jun+08/26614202.html si-local-file:///var/storage/secattach/20260608/26614202.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Seaport+Therapeutics%2C+++++For%3A+Jun+08/26614202.html Mon, 08 Jun 2026 07:12:00 -0400 SPTX http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Press+Releases/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX http://www.streetinsider.com/Business+Wire/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Business+Wire/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX http://www.streetinsider.com/Business+Wire/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html <p class="bwalignc"> <i>New data from Phase 1 trial of GlyphAgoTM build upon previously reported topline data and further demonstrate GlyphAgoTM can achieve therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce or eliminate the need for liver function testing</i> </p><p class="bwalignc"> <i>Enrollment in Phase 2b BUOY-1 trial of GlyphAlloTM is on track with topline data expected in 1H 2027; Seaport dosed first participant in Phase 1 driving simulation trial of GlyphAlloTM, with data expected in 2H 2026</i> </p><p class="bwalignc"> <i>Dr. Sharon Mates, Co-Founder, Chair, and CEO of Intra-Cellular Therapies until its acquisition by Johnson &amp; Johnson for $14.6 billion, was http://www.streetinsider.com/Business+Wire/Seaport+Therapeutics+Reports+First+Quarter+2026+Financial+Results+and+Highlights+Recent+Corporate+and+Clinical+Progress/26614175.html Mon, 08 Jun 2026 07:05:00 -0400 A.06822034 A.17471648 O.17008112 O.20026344 SPTX